Insulet (NASDAQ:PODD) Surprises With Q4 CY2025 Sales

robot
Abstract generation in progress

Insulet (NASDAQ:PODD) reported strong Q4 CY2025 results, with sales of $783.8 million exceeding analyst expectations by 2% and non-GAAP EPS of $1.55 beating estimates by 6%. The company’s revenue grew 31.2% year-on-year, and it provided Q1 CY2026 revenue guidance largely in line with analyst predictions. Insulet emphasized its robust business model and disciplined execution as key drivers for its continued success in revolutionizing diabetes care.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)